-$0.53 Earnings Per Share Expected for ChemoCentryx, Inc. (NASDAQ:CCXI) This Quarter

Analysts predict that ChemoCentryx, Inc. (NASDAQ:CCXIGet Rating) will announce ($0.53) earnings per share (EPS) for the current quarter, Zacks reports. Six analysts have made estimates for ChemoCentryx’s earnings. The lowest EPS estimate is ($0.64) and the highest is ($0.38). ChemoCentryx posted earnings per share of ($0.56) in the same quarter last year, which indicates a positive year over year growth rate of 5.4%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that ChemoCentryx will report full year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($2.44) to ($0.91). For the next financial year, analysts forecast that the firm will post earnings of ($0.57) per share, with EPS estimates ranging from ($1.75) to $3.58. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover ChemoCentryx.

ChemoCentryx (NASDAQ:CCXIGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.24). ChemoCentryx had a negative net margin of 514.64% and a negative return on equity of 45.26%. During the same quarter last year, the business posted ($0.43) EPS.

CCXI has been the topic of several recent research reports. StockNews.com initiated coverage on shares of ChemoCentryx in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $85.00 price objective on shares of ChemoCentryx in a report on Friday, March 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, ChemoCentryx presently has an average rating of “Buy” and a consensus price target of $73.43.

Shares of ChemoCentryx stock opened at $17.38 on Friday. The company has a current ratio of 4.27, a quick ratio of 4.26 and a debt-to-equity ratio of 0.02. ChemoCentryx has a 12-month low of $9.53 and a 12-month high of $42.16. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -8.65 and a beta of 1.96. The firm’s 50 day simple moving average is $22.63 and its two-hundred day simple moving average is $29.87.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Total Clarity Wealth Management Inc. purchased a new stake in ChemoCentryx during the fourth quarter worth $29,000. CWM LLC purchased a new stake in ChemoCentryx during the fourth quarter worth $37,000. UMB Bank N A MO purchased a new stake in ChemoCentryx during the fourth quarter worth $37,000. Paragon Capital Management Ltd purchased a new position in ChemoCentryx during the fourth quarter valued at $42,000. Finally, Lazard Asset Management LLC purchased a new position in ChemoCentryx during the fourth quarter valued at $60,000. 82.28% of the stock is currently owned by hedge funds and other institutional investors.

ChemoCentryx Company Profile (Get Rating)

ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Featured Stories

Get a free copy of the Zacks research report on ChemoCentryx (CCXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.